Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “pd-”

81 pharma patents match "pd-" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 81
Index total 30,257
Page 3 / 4

Quick answer

This filtered view shows 81 pharmaceutical patents matching "pd-" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

81 results for “pd-” · 30,257 patents in full index Clear search

  1. US 11421034

    Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer

    Five Prime Therapeutics, Inc. · Granted Aug 23, 2022 · Expires Aug 18, 2042

    granted
  2. US 11357842

    PD-L1 targeting DNA vaccine for cancer immunotherapy

    Vaximm AG · Granted Jun 14, 2022 · Expires Jun 9, 2042

    granted
  3. US 11324822

    Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer

    Syndax Pharmaceuticals, Inc. · Granted May 10, 2022 · Expires May 5, 2042

    granted
  4. US 11292842

    Anti-PD-1 antibodies for treatment of lung cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  5. US 11254752

    Methods for treating cancer with bispecific anti-CD3xMUC16 antibodies and anti-PD-1 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 22, 2022 · Expires Feb 17, 2042

    granted
  6. US 11254746

    Anti-PD-1 monoclonal antibody, and preparation method therefor and application thereof

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Granted Feb 22, 2022 · Expires Feb 17, 2042

    granted
  7. US 11141434

    Programmed death 1 ligand 1 (PD-L1) binding proteins and methods of use thereof

    Iovance Biotherapeutics, Inc. · Granted Oct 12, 2021 · Expires Oct 7, 2041

    granted
  8. US 11117970

    Human antibodies to PD-L1

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 14, 2021 · Expires Sep 9, 2041

    granted
  9. US 10982215

    Polynucleotide agents targeting programmed cell death 1 ligand 1 (PD-L1) and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  10. WO 2021064188

    COMBINAISON COMPRENANT UN INHIBITEUR DE HDAC, UN INHIBITEUR DE CTLA-4 ET UN INHIBITEUR DE PD-1 OU UN INHIBITEUR DE PD-L1 POUR LE TRAITEMENT DU CANCER

    4SC AG [DE] · Granted Apr 8, 2021 · Expires Apr 3, 2041

    granted
  11. US 10889813

    Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jan 12, 2021 · Expires Jan 7, 2041

    granted
  12. US 10858432

    Antibodies specific to glycosylated PD-1 and methods of use thereof

    The Board of Regents of the University of Texas System · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted
  13. US 10836827

    Antibodies specific to glycosylated PD-L1 and methods of use thereof

    The Board of Regents of the University of Texas System · Granted Nov 17, 2020 · Expires Nov 12, 2040

    granted
  14. US 10822414

    Anti-PD-1 antibodies, compositions comprising anti-PD-1 antibodies and methods of using anti-PD-1 antibodies

    Sutro Biopharma, Inc. · Granted Nov 3, 2020 · Expires Oct 29, 2040

    granted
  15. US 10786552

    Il-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody

    Nektar Therapeutics · Granted Sep 29, 2020 · Expires Sep 24, 2040

    granted
  16. US 10744116

    Detection and treatment of anti-PD-1 therapy resistant metastatic melanomas

    The Regents of the University of California · Granted Aug 18, 2020 · Expires Aug 13, 2040

    granted
  17. US 10745704

    Compositions and methods for inhibiting expression of CD274/PD-L1 gene

    Alnylam Pharmaceuticals, Inc. · Granted Aug 18, 2020 · Expires Aug 13, 2040

    granted
  18. US 10737113

    Human antibodies to PD-1

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 11, 2020 · Expires Aug 6, 2040

    granted
  19. US 10736976

    Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 11, 2020 · Expires Aug 6, 2040

    granted
  20. US 10683347

    Treatment of cancer using anti-TGF-β and anti-PD-1 antibodies

    The Regents of the University of California · Granted Jun 16, 2020 · Expires Jun 11, 2040

    granted
  21. US 10618967

    Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer

    Five Prime Therapeutics, Inc. · Granted Apr 14, 2020 · Expires Apr 9, 2040

    granted
  22. EP 3630112

    KOMBINATION AUS REGORAFENIB UND PD-1/PD-L1(2)-INHIBITOREN ZUR BEHANDLUNG VON KREBS

    BAYER AG [DE] · Granted Apr 8, 2020 · Expires Apr 3, 2040

    granted
  23. US 10457725

    Methods of treating skin cancer by administering a PD-1 inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 29, 2019 · Expires Oct 24, 2039

    granted
  24. CA 3097087

    COMBINAISON COMPRENANT UN INHIBITEUR DE HDAC, UN INHIBITEUR DE LAG-3 ET UN INHIBITEUR DE PD-1 OU UN INHIBITEUR DE PD-L1 POUR LE TRAITEMENT DU CANCER

    4SC AG [DE] · Granted Oct 24, 2019 · Expires Oct 19, 2039

    granted